Clinical Trial Update: Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry reports a Phase 2 trial evaluating empagliflozin for preserving residual kidney function in incident peritoneal dialysis patients,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication | Phase 2 | Status: RECRUITING